Unique co-operation with regard to the treatment of diabetes and obesity in the United Arab Emirates

Unique co-operation with regard to the treatment of diabetes and obesity in the
United Arab Emirates

Global Health Partner has signed a contract with the Ministry of Health in the
United Arab Emirates regarding the setting up and running of a combined diabetes
and obesity clinic.
“The incidence of obesity and diabetes is very high in the Middle East.
Scientific studies have shown that obesity operations have a very positive
effect on diabetes, and through this unique clinic Global Health Partner now has
the opportunity to be at the leading edge with regard to evaluating this,” says
Per Båtelson, Global Health Partner's CEO.

Global Health Partner has signed a contract with the Ministry of Health in the
United Arab Emirates regarding the setting up and running of a combined obesity
and diabetes clinic in Ajman, an Emirate that is about fifty kilometres from
Dubai. The clinic, which will be the first of its kind in the region, with a
combination of highly specialized obesity and diabetes care, is immediately
adjacent to the public Sheikh Khalifa Hospital. Initially the clinic will focus
on outpatient care, with additional limited volumes of inpatient obesity
surgery. The aim is to gradually expand the inpatient care. Under the agreement
Global Health Partner has full responsibility for leading and running the
business. The term of the contract is initially five years and Global Health
Partner will receive a combination of a fixed fee for running the business and
for managerial responsibility and a variable fee for surgery.

The prevalence of obesity in the United Arab Emirates is approximately 30% and
just over 20% of the population suffers from diabetes. This means that the
United Arab Emirates is one of the countries in the world with the highest
prevalence of both obesity and diabetes. Diabetes type II is a commonly
occurring secondary disease in people suffering from obesity and can lead to
complications in the eyes, kidneys, heart etc. In many countries diabetes is the
single most expensive disease for society. In recent years many scientific
studies have been able to show that obesity operations performed on patients
with both obesity and diabetes lead to the diabetes totally regressing in 50-80%
of the patients and to other patients improving considerably. Other
weight-reducing treatment can also lead to diabetes type II improving
significantly. Institutions and organizations in various parts of the world are
therefore beginning to look at the advantages of combining these areas of
treatment.     

Global Health Partner already has clinics for the treatment of obesity in
Stockholm, Lund, Bergen, Birmingham and Cairo. The clinics are run under the
name Bariatric Centers within Service Line Bariatrics.

14 May 2009
Gothenburg, Sweden 
Global Health Partner AB (publ)
Per Båtelson, CEO

For further information, please contact:
Per Båtelson, CEO, tel: +46 (0)705-95 57 00
Anna Ahlberg, Head of Investor Relations, tel: +46 (0)708-55 38 35

Global Health Partner operates specialist clinics that focus on selected
treatment areas (Spine, Dental, Bariatrics and Orthopaedics) using a business
model unique in the Swedish healthcare sector in which leading physicians become
partners and shareholders. Operating clinics with a high patient volume in a
particular treatment area leads to a higher level of efficiency and quality.
This concept of “Quality through Specialisation” is the foundation for the
clinics and Global Health Partner's operations. Global Health Partner's shares
are traded on the Small Cap list at NASDAQ OMX Stockholm under the abbreviation
“GHP.”

Global Health Partner AB (publ) is required to publish the information herein
according to the Swedish Securities Market Act. This information was published
on 14 May 2009 at 12.30 pm CET.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.